GPBAR1 and metabolic dysfunction-associated steatohepatitis: In other contexts, like a specific NASH model, TGR5 activation appeared less critical than FXR activation for therapeutic benefit (85), and in a colon cancer metastasis model, TGR5 downregulation correlated with improved outcomes (101).